We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Breakthrough of PARP inhibitors resistance treating with the local therapy in recurrent epithelial ovarian cancer patients with oligo-progression.
- Authors
Jung Yun Lee; Ji Eun Lee; Sang Wun Kim; Sunghoon Kim; Young Tae Kim
- Abstract
Objective: The purpose of this study is to find out whether the local therapy (cytoreductive surgery [CRS] or radiotherapy) is effective in recurrent epithelial ovarian cancer patients who have oligo-progressed on poly (ADP-ribose) polymerase inhibitors (PARPi) maintenance. Methods: By retrospective medical record review, this study evaluated the effectiveness of the CRS in patients with high grade ovarian cancer after local treatment for oligometastatic progression. The main objective was to assess progression-free survival (PFS) and overall survival (OS) under PARPi after local therapy. Results: Twenty patients who were diagnosed with recurrent ovarian cancer while on PARPi maintenance and then treated local therapy were identified in Yonsei Cancer Center from January 2015 and August 2023. The 33.3% of patients were BRCA mutated and 94.4% of patients were stage 3 or 4. Among the 18 patients, 16 patients (88.9%) were high grade serous ovarian cancer (HGOC), 1 patient (5.5%) were endometrioid carcinoma, and 1 patient (5.5%) were both histology type. Main progression sites were large bowel (18.8%), diaphragm (15.6%), peritoneum (9.4%), liver (9.4%), and spleen (6.3%). Local therapies included surgery (75%), radiotherapy (18.8%), and both (6.2%). Median OS was 16.3 month (95% confidence interval [CI]=13.8-31.8) and median PFS was 9.0 month (95% CI=4.4-13.6). There were no significant differences in PFS according to the number of metastatic sites. Conclusion: The CRS or radiotherapy is associated with beneficial effect in patients who have oligo-progression on PARPi maintenance.
- Subjects
OVARIAN epithelial cancer; CANCER patients; POLY(ADP-ribose) polymerase; LARGE intestine; CYTOREDUCTIVE surgery; OVARIAN cancer
- Publication
Journal of Gynecologic Oncology, 2024, Vol 35, p42
- ISSN
2005-0380
- Publication type
Academic Journal
- DOI
10.3802/jgo.2024.35.S2.P42